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volume delineation. Reasons for non-compliance are mostly 
problems with target coverage. Thirty-eight percent of the 
centers reported issues with target coverage; in 1 center 
they interpret the Dose Volume Histogram differently and are 
now looking at the 85% coverage of the planning target 
volume instead of the 95%. 
Conclusions: The introduction of new delineation guidelines 
for the RNA in breast radiotherapy has a major impact on the 
treatment planning and dosimetry with especially introducing 
newer treatment techniques to achieve better target 
coverage. Surprisingly, not all centers use the centrally 
reviewed and corrected target delineation to guide their 
radiotherapy to the RNA.  
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Purpose/Objective: In the era of fast technological evolution 
in breast radiotherapy (RT), a correct delineation of the 
target volumes becomes more and more important. The 
objective in this study is to investigate the performance of 
the accuracy of the delineation of the regional nodal areas 
(RNA) by different radiation-oncologists and to determine the 
most difficult regions to contour. 
Materials and Methods: Before the start of the national 
central review study for the delineation of the RNA in breast 
RT, all participating centers were asked to delineate all the 
different RNA on a CT-scan with intravenous contrast of one 
specific patient. The delineation guidelines as well as the 
delineation atlases, covering both target volumes and normal 
anatomy, were provided. The obtained contours were 
compared with the reference contour to evaluate the 
conformity using the overlapping volume (OV). The OV is 
defined by the intersection of the obtained contour with the 
reference contour divided by the union of those contours.  
Results: Twenty-two radiation-oncologists of 15 different 
radiotherapy departments performed the delineation of the 
RNA of that one specific case. In general, the mean OV of all 
lymph node regions together was 0.52 (± std 0.12). The most 
problematic areas were the rotter space and the internal 
mammary lymph node region (figure), with a mean OV of 
respectively 0.42 (± std 0.09) and 0.48 (± std 0.09). Level IV 
(= supraclavicular) and level I of the axilla were contoured 
the best with a mean OV of 0.6 (± std 0.13) and 0.56 (± std 
0.08), followed by level III and level II of the axilla with a 
mean OV of respectively 0.53 (± std 0.11) and 0.51 (± std 
0.11). 
Conclusions: Delineation of the regional nodal areas in breast 
radiotherapy is not easy with a large intercenter and 
interobserver variation, even in the presence of extensively 
written guidelines and clear atlases. The most difficult areas 
to contour in this pilot study were the rotter space and the 
internal mammary node region. The national central review 
study will tell us if practicing and central review lead to 
better contouring. 
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Purpose/Objective: Upper abdominal SBRT is significantly 
compromised by late toxicity to bowel structures, mostly 
stomach, duodenum and small bowel and to a lesser degree 
also colon. Often ablative doses cannot be prescribed without 
infringement of dose constraints to bowel organs at risk 
(OAR), limiting SBRT to selected places had distant from 
bowel structures. 
Materials and Methods: We developed a method of SBRT 
where all doses were prescribed according to ICRU 
guidelines. After generation of the main planning target 
volume (PTV) by isotropic expansion of 4 mm from internal 
target volume (ITV) as determined by 4D-imaging. We then 
defined a high dose SIB-PTV by a negative margin of 10 mm of 
the ITV. Dose prescribed to the SIB-PTV was 122-125% of the 
dose prescribed to the main PTV. Additionally, we defined a 
SIP-PTV by subtracting the planning risk volume (PRV) of a 
bowel OAR created by a 4 mm margin expansion of the OAR 
structure. Dose prescribed to the SIP-PTV was chosen to meet 
the defined dose constraints to OARs as described by 
Timmerman in 2008. Two fractionation regimes were used, 5 
or 12 fractions, given every other day. Five fraction regimens 
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were chosen when closeness of the PTV to the bowel was 
intermediate and doses were 5 x 6.5/9.0/11.0 Gy to 
SIP/main/SIB PTV. 12 fraction regimens were preferred in 
patients with large contact interfaces to bowel OARs and 
doses were 12 x 3.5/4.0/5.0 Gy to SIP/main/SIB PTV. If in 
doubt, a plan for 5 fractions was created and if dose 
constraints were violated a new plan for 12 fractions was 
made. Original dose constraints for OARs for 12 fractions 
were recalculated using EQD2 (equivalent dose in 2 Gy 
fractions) with α/β 3 for late bowel toxicity in an attempt to 
achieve isotoxicity. Proton pump inhibitors (PPI) were 
prescribed prior to SBRT for at least 6 months after 
completion of therapy. 
Results: Since 08/2013 25 patients with the SIB-SIP concept 
were treated with hepatic metastases, primary hepatic 
lesions, Klatskin tumours and pancreatic cancer (PDAC). Most 
often SIP-volumes were small compared to the main PTV and 
14 patients could be treated with 5 fractions, whereas in 11 
patients a 12 fraction regimen was preferred. Acute toxicity 
was < grade 2 in 23 patients. One patient with PDAC had 
grade 3 pain after the 1st of planned 5 fractions which did not 
re-occur after change to the 12-fraction-regimen single 
doses. One patient with PDAC had Forrest grade III gastric 
ulceration after 24/48 Gy (main PTV) despite prophylactic PPI 
intake. None of the patients developed late gastrointestinal 
complications >= grade 2 after a median follow-up of 9 
months and local control rate at 9 months was 81%. 
Conclusions: We here present a novel ICRU-type prescription 
technique for upper abdominal SBRT combining protection of 
bowel OARs with directed boost to the core regions of the 
lesion with favourable initial clinical tolerance and local 
tumour efficacy.  
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Purpose/Objective: The purpose of this study was to analyze 
intra-fractional positioning uncertainty for stereotactic 
radiotherapy and radiosurgery of cranial tumors, including 
primary brain tumors and metastatic disease. Specifically, we 
wish to determine if the use of intra-fractional image guided 
patient positioning verification is necessary during delivery of 
'frameless' stereotactic radiotherapy and radiosurgery 
(SRT/SRS) and non-coplanar radiation beams, and if 
positioning uncertainty is associated with overall treatment 
time.  
Materials and Methods: The patients were treated on an 
accelerator-based stereotactic equipment (NovalisTx with 
micoMLC, Varian/BrainLab). Orthogonal radiographic 
treatment verification data was extracted for 288 
consecutive patients and 1344 fractions, and were analyzed 
with respect to 3D translational and angular corrections once 
during treatment delivery of SRT/SRS (ExacTrac, BrainLab). 
The treatment position was adjusted using 6D corrections 
(Robotics, BrainLab). Association was investigated using 
Spearman signed rank test and p-values less than 0.05 were 
considered significant.  
Results: The study shows that positioning corrections greater 
than 2 mm are required for ca. 6% of the beams (see Fig.1). 
Further, the magnitude of the translational corrections and 
the maximum angular deviations were both significantly 
associated with the delay time between the beams (p<0.006) 
(see Table 1). In addition, the maximum angular and 
translational deviations were associated (p<0.001).  
Table 1. Spearman correlation coefficients for the treatment 
beams investigated.  
 
Parameter Association Rho 
Significance  
(2-tailed) 
Lateral dev. Long. dev. -0.007 0.785 
Vertical dev. Long. dev. -0.039 0.157 
Lateral dev. Vertical dev. -0.012 0.672 
Max angular dev. Delay time 0.092 0.006 
3D deviation Delay time 0.376 0.000 
3D deviation 
Max angular 
dev. 
0.174 0.000 
 
Conclusions: We conclude that a subgroup of SRT/SRS 
patients may have considerable positioning error unless this is 
monitored and corrected during treatment, and that keeping 
the imaging and delivery times short is beneficial towards 
clinically relevant geographical misses.  
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Purpose/Objective: To identify the main pitfalls and 
challenges and their possible sources in clinical target volume 
